DOP2013000029A - Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos - Google Patents

Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos

Info

Publication number
DOP2013000029A
DOP2013000029A DO2013000029A DO2013000029A DOP2013000029A DO P2013000029 A DOP2013000029 A DO P2013000029A DO 2013000029 A DO2013000029 A DO 2013000029A DO 2013000029 A DO2013000029 A DO 2013000029A DO P2013000029 A DOP2013000029 A DO P2013000029A
Authority
DO
Dominican Republic
Prior art keywords
n3pglu
amiloide
peptidic
same
antibodies
Prior art date
Application number
DO2013000029A
Other languages
English (en)
Inventor
Ying Tang
Jirong Lu
Ronald Bradley Demattos
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2013000029A publication Critical patent/DOP2013000029A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos A3 anti-N3pGlu o fragmento de unión al antígeno de los mismos. Además, la presente invención proporciona el uso de los anticuerpos Aí3 anti-N3pGlu o fragmento de unión al antígeno de los mismos para el tratamiento de la enfermedad de Alzheimer.
DO2013000029A 2010-08-12 2013-02-05 Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos DOP2013000029A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37302610P 2010-08-12 2010-08-12

Publications (1)

Publication Number Publication Date
DOP2013000029A true DOP2013000029A (es) 2013-03-15

Family

ID=44543826

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000029A DOP2013000029A (es) 2010-08-12 2013-02-05 Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos

Country Status (41)

Country Link
US (2) US8679498B2 (es)
EP (3) EP3339323B1 (es)
JP (2) JP5980207B2 (es)
KR (1) KR101498833B1 (es)
CN (2) CN105111308B (es)
AU (1) AU2011289629B2 (es)
BR (1) BR112013004056B8 (es)
CA (1) CA2805114C (es)
CL (1) CL2013000390A1 (es)
CO (1) CO6670526A2 (es)
CR (1) CR20130016A (es)
CY (2) CY1120144T1 (es)
DK (3) DK3339323T3 (es)
DO (1) DOP2013000029A (es)
EA (1) EA023021B1 (es)
EC (1) ECSP13012436A (es)
ES (3) ES2564252T3 (es)
FI (1) FIC20250038I1 (es)
FR (1) FR25C1055I1 (es)
GT (1) GT201300036A (es)
HR (3) HRP20160151T1 (es)
HU (2) HUE028678T2 (es)
IL (2) IL285226B2 (es)
LT (3) LT3042917T (es)
MA (1) MA34461B1 (es)
ME (3) ME03032B (es)
MX (2) MX342782B (es)
MY (2) MY163521A (es)
NL (1) NL301359I2 (es)
NO (2) NO3042917T3 (es)
NZ (2) NZ626665A (es)
PE (1) PE20130817A1 (es)
PH (1) PH12013500277A1 (es)
PL (3) PL2603523T3 (es)
PT (2) PT3339323T (es)
RS (3) RS59652B1 (es)
SG (2) SG187586A1 (es)
SI (3) SI2603523T1 (es)
UA (1) UA107600C2 (es)
WO (1) WO2012021469A1 (es)
ZA (1) ZA201300437B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
DK3339323T3 (da) * 2010-08-12 2020-01-20 Lilly Co Eli Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
CA2938129A1 (en) * 2014-02-03 2015-08-06 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
CA2954476C (en) 2014-07-10 2023-09-19 Novartis Ag Immune-stimulating monoclonal antibodies against human interleukin-2
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
KR102777500B1 (ko) * 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
HK1257518A1 (zh) 2016-01-11 2019-10-25 Novartis Ag 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
AR107783A1 (es) * 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
TW201740954A (zh) * 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3496750A2 (en) * 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
JP2019530647A (ja) 2016-08-18 2019-10-24 イーライ リリー アンド カンパニー Ｂａｃｅ−１阻害剤と抗ｎ３ｐｇｌｕ ａベータ抗体の併用療法
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
BR112018013084A2 (pt) 2016-10-28 2018-12-11 H Lundbeck As tratamentos de combinação compreendendo a administração de imidazopirazinonas
SG11201903770UA (en) 2016-10-28 2019-05-30 H Lundbeck As Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
TWI705975B (zh) * 2017-04-20 2020-10-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
LT3723807T (lt) 2017-12-14 2021-12-10 H. Lundbeck A/S Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
KR20260053095A (ko) * 2018-02-11 2026-04-20 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도
MX2020009507A (es) * 2018-03-13 2020-10-22 Smivet B V Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos.
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
MA55491A (fr) * 2019-03-26 2022-02-09 Janssen Pharmaceutica Nv Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
US20230250193A1 (en) * 2020-06-17 2023-08-10 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
IL301572A (en) * 2020-10-02 2023-05-01 Lilly Co Eli Methods for reducing the protein content of the host cell in protein purification processes
TWI843040B (zh) * 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
CN118139880A (zh) 2021-10-22 2024-06-04 伊莱利利公司 O-连接的n-乙酰葡糖胺水解酶(oga)抑制剂联合治疗
TW202334210A (zh) 2021-10-29 2023-09-01 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
AU2022376940A1 (en) 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
KR20240105403A (ko) 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
AU2022376930A1 (en) 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
JP2025506411A (ja) 2022-02-03 2025-03-11 イーライ リリー アンド カンパニー アルツハイマー病の診断及び治療のための局所タウイメージング
AU2023309007A1 (en) 2022-07-21 2025-01-30 Eli Lilly And Company PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF
EP4638494A1 (en) 2022-12-22 2025-10-29 BioArctic AB Antibody which binds to abetape3
WO2025106313A1 (en) 2023-11-14 2025-05-22 Eli Lilly And Company Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
WO2025228315A1 (en) * 2024-04-28 2025-11-06 Jacobio Pharmaceuticals Co., Ltd. Anti-n3pglu amyloid beta antibodies and uses thereof
WO2025237397A1 (zh) * 2024-05-16 2025-11-20 江苏恒瑞医药股份有限公司 抗N3pGlu Aβ抗体及其医药用途
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
TW202607032A (zh) 2024-06-20 2026-02-16 瑞典商生物極公司 雙特異性結合分子
WO2026012421A1 (zh) * 2024-07-11 2026-01-15 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途
WO2026055601A1 (en) 2024-09-09 2026-03-12 Eli Lilly And Company METHOD OF TREATING ALZHEIMER'S DISEASE USING ANTI-N3pGlu AMYLOID BETA ANTIBODIES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
AU2005217596B2 (en) * 2004-02-23 2012-01-19 Eli Lilly And Company Anti-ABeta antibody
GEP20115195B (en) * 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
EP2146746A4 (en) * 2007-04-18 2011-03-23 Janssen Alzheimer Immunotherap PREVENTIVE AND TREATING ZEREBRALER AMYLOID ANGIOPATHY
WO2009149487A2 (en) 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
CA2730073A1 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
EP3338795A1 (en) * 2008-07-21 2018-06-27 Probiodrug AG Diagnostic antibody assay
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
DK3339323T3 (da) * 2010-08-12 2020-01-20 Lilly Co Eli Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf

Also Published As

Publication number Publication date
HUE037524T2 (hu) 2018-09-28
SG10201509330XA (en) 2015-12-30
MX355268B (es) 2018-04-11
CN103068848A (zh) 2013-04-24
CN105111308A (zh) 2015-12-02
ES2764728T3 (es) 2020-06-04
JP5980207B2 (ja) 2016-08-31
ME03032B (me) 2018-10-20
CR20130016A (es) 2013-03-21
JP2016179985A (ja) 2016-10-13
ECSP13012436A (es) 2013-03-28
BR112013004056B8 (pt) 2022-10-18
MY181969A (en) 2021-01-15
ES2664128T3 (es) 2018-04-18
PL3339323T3 (pl) 2020-05-18
CO6670526A2 (es) 2013-05-15
EA201270813A1 (ru) 2013-05-30
MX2013001716A (es) 2013-10-28
PL2603523T3 (pl) 2016-07-29
FR25C1055I1 (fr) 2026-03-06
IL224030B (en) 2022-04-01
HRP20192233T1 (hr) 2020-03-06
CN105111308B (zh) 2019-03-12
DK3042917T3 (en) 2018-04-23
RS57026B1 (sr) 2018-05-31
RS59652B1 (sr) 2020-01-31
LT3042917T (lt) 2018-05-10
KR101498833B1 (ko) 2015-03-04
SG187586A1 (en) 2013-03-28
IL285226B2 (en) 2023-02-01
FIC20250038I1 (fi) 2025-12-18
ME02352B (me) 2016-06-20
CY1120144T1 (el) 2018-12-12
CL2013000390A1 (es) 2014-03-21
AU2011289629A1 (en) 2013-02-14
HK1180703A1 (zh) 2013-10-25
CY1122458T1 (el) 2021-01-27
PL3042917T3 (pl) 2018-07-31
PH12013500277A1 (en) 2017-04-21
WO2012021469A1 (en) 2012-02-16
AU2011289629B2 (en) 2014-07-03
EP3042917A1 (en) 2016-07-13
BR112013004056B1 (pt) 2022-05-17
SI2603523T1 (sl) 2016-04-29
RS54685B1 (sr) 2016-08-31
NO2025056I1 (no) 2025-12-11
MX342782B (es) 2016-10-12
NL301359I2 (nl) 2026-02-10
LT3339323T (lt) 2020-02-10
KR20130051989A (ko) 2013-05-21
GT201300036A (es) 2014-07-16
IL285226A (en) 2021-09-30
SI3042917T1 (en) 2018-04-30
NZ606095A (en) 2014-11-28
US8679498B2 (en) 2014-03-25
HUE028678T2 (en) 2016-12-28
US20130142806A1 (en) 2013-06-06
EP3339323A1 (en) 2018-06-27
EP3042917B1 (en) 2018-02-21
CA2805114A1 (en) 2012-02-16
PE20130817A1 (es) 2013-07-18
DK3339323T3 (da) 2020-01-20
JP2013536191A (ja) 2013-09-19
CN103068848B (zh) 2015-11-25
EP2603523B1 (en) 2016-01-27
DK2603523T3 (en) 2016-03-21
EA023021B1 (ru) 2016-04-29
ES2564252T3 (es) 2016-03-21
PT3339323T (pt) 2020-01-14
HRP20160151T1 (hr) 2016-03-11
IL285226B (en) 2022-10-01
CA2805114C (en) 2017-12-05
LTPA2026504I1 (es) 2026-02-10
EP2603523A1 (en) 2013-06-19
SI3339323T1 (sl) 2019-12-31
JP6395755B2 (ja) 2018-09-26
US20140065138A1 (en) 2014-03-06
MA34461B1 (fr) 2013-08-01
NZ626665A (en) 2016-04-29
UA107600C2 (uk) 2015-01-26
PT3042917T (pt) 2018-05-02
EP3339323B1 (en) 2019-11-13
ZA201300437B (en) 2014-06-25
ME03661B (me) 2020-07-20
US8961972B2 (en) 2015-02-24
BR112013004056A2 (pt) 2020-08-04
MY163521A (en) 2017-09-15
HRP20180616T1 (hr) 2018-07-13
NO3042917T3 (es) 2018-07-21

Similar Documents

Publication Publication Date Title
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CY1116842T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CL2019000643A1 (es) Anticuerpos de unión a cd3.
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
AU2018256498A1 (en) Antibodies to amyloid beta
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201171060A1 (ru) Молекулы антител, обладающих специфичностью к человеческому ох40
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
BR112014011404A2 (pt) moléculas de anticorpos com especificidade para o ox40 humano
CU20120095A7 (es) Antagonistas de pcsk9
MX358249B (es) Proteínas de enlace al antígeno il-23 humanas.
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
CL2014000679A1 (es) Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada; y método para producir anticuerpo
EA201400579A1 (ru) Антитела к il-36r
CR20130126A (es) Anticuerpos anti-ox40 y métodos de uso de los mismos
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
AR124605A2 (es) Anticuerpos anti-il-36r
CY1117265T1 (el) Αντισωματα aνti-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων